What's new? Log in Free sign up

Filing search / Olema Pharmaceuticals, Inc. / "Satisfaction"

Search information

Olema Pharmaceuticals, Inc.

Companies

"Satisfaction"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

53 results

Newest first Best match first

OLMA Olema Pharmaceuticals, Inc.

Quarterly report

and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time-consuming … attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required

6 Aug 24

4:15pm

OLMA Olema Pharmaceuticals, Inc.

Quarterly report

be marketed. Satisfaction of these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. We cannot … associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions

8 May 24

4:15pm

OLMA Olema Pharmaceuticals, Inc.

to the satisfaction of the FDA. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under … in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time

11 Mar 24

4:15pm

OLMA Olema Pharmaceuticals, Inc.

Act. The Company has complied to the Commission’s satisfaction with all requests of the Commission for additional or supplemental information related … satisfaction (or waiver by the Agent in its sole discretion) of the following additional conditions: (a) Registration Statement Effective. The Registration

11 Mar 24

4:15pm

OLMA Olema Pharmaceuticals, Inc.

Entry into a Material Definitive Agreement

Statement have or will have been declared effective by the Commission under the Securities Act. The Company has complied to the Commission’s satisfaction … , to the completion by TD Cowen of a due diligence review satisfactory to TD Cowen in its reasonable judgment, and to the continuing satisfaction (or waiver by TD Cowen

Prospectus supplement for primary offering

vwzoqbelby7bn37q9t

Quarterly report

7 Nov 23

4:12pm

Olema Oncology Announces Combined Financing for Up to $180 Million

4jetse6zxlsww9bxmx9

Olema Oncology Announces Combined Financing for Up to $180 Million

x65e7xuu64kfjq8

Quarterly report

8 Aug 23

4:12pm

4c798pxl5sovnbps4xb

Quarterly report

9 May 23

4:08pm

63dx1ddk5gmi6mro

Quarterly report

9 May 23

4:08pm

Quarterly report

9 May 23

4:08pm

Quarterly report

8 Nov 22

4:45pm

Quarterly report

9 Aug 22

12:00am

Quarterly report

9 May 22

4:44pm

nb6v1q u7naz6n6d3kvr

Shelf registration

7efn n0wk938k376la

Shelf registration

Shelf registration

Shelf registration

Prev
1
2
3
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.